Recent advances in the applications of iPSC technology

Wiegand, Connor; Banerjee, Ipsita

doi:10.1016/j.copbio.2019.05.011

Cited by 57 publications

(41 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficient differentiation of iPSCs into various cell populations such as neural cells, cardiomyocytes, hepatic cells, ECs, VSMCs, etc. has been demonstrated in literature [261,262]. However, this technology has not yet received FDA approval for human clinical use, and therefore their applicability is limited even in vascular engineering [263,264].…”

Section: Discussionmentioning

confidence: 99%

Future Perspectives in Small-Diameter Vascular Graft Engineering

et al. 2020

View full text Add to dashboard Cite

The increased demands of small-diameter vascular grafts (SDVGs) globally has forced the scientific society to explore alternative strategies utilizing the tissue engineering approaches. Cardiovascular disease (CVD) comprises one of the most lethal groups of non-communicable disorders worldwide. It has been estimated that in Europe, the healthcare cost for the administration of CVD is more than 169 billion €. Common manifestations involve the narrowing or occlusion of blood vessels. The replacement of damaged vessels with autologous grafts represents one of the applied therapeutic approaches in CVD. However, significant drawbacks are accompanying the above procedure; therefore, the exploration of alternative vessel sources must be performed. Engineered SDVGs can be produced through the utilization of non-degradable/degradable and naturally derived materials. Decellularized vessels represent also an alternative valuable source for the development of SDVGs. In this review, a great number of SDVG engineering approaches will be highlighted. Importantly, the state-of-the-art methodologies, which are currently employed, will be comprehensively presented. A discussion summarizing the key marks and the future perspectives of SDVG engineering will be included in this review. Taking into consideration the increased number of patients with CVD, SDVG engineering may assist significantly in cardiovascular reconstructive surgery and, therefore, the overall improvement of patients’ life.

show abstract

Section: Discussionmentioning

confidence: 99%

Future Perspectives in Small-Diameter Vascular Graft Engineering

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the context of modern medicine, iPSCs find many applications: they can be derived from a patient and used to study the mechanism of a known disease to find specific targets for therapy; or to identify the function of genes associated with a novel disease; and finally to screen compounds in a large scale and to derive specific treatments. This approach would particularly benefit those rare diseases for which clinical trials could not be designed due to a very limited number of patients (78).…”

Section: Induced Pluripotent Stem Cells (Ipscs) and Applicationsmentioning

confidence: 99%

Novel approaches to liver disease diagnosis and modeling

Oliveira¹,

Fiorotto²

2021

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

Lack of a prompt and accurate diagnosis remains on top of the list of challenges faced by patients with rare liver diseases. Although rare liver diseases affect a significant percentage of the population as a group, when taken singularly they represent unique diseases and the approaches used for diagnosis of common liver diseases are insufficient. However, the development of new methods for the acquisition of molecular and clinical data (i.e., genomic, proteomics, metabolomics) and computational tools for their analysis and integration, together with advances in modeling diseases using stem cell-based technology [i.e., induced pluripotent stem cells (iPSCs) and tissue organoids] represent a promising and powerful tool to improve the clinical management of these patients. This is the goal of precision medicine, a novel approach of modern medicine that aims at delivering a specific treatment based on disease-specific biological insights and individual profile. This review will discuss the application and advances of these technologies and how they represent a new opportunity in hepatology.

show abstract

“…The phenotype ranges that can be investigated by iPSC models involve a broad range of molecular, metabolic, electrophysiological, and cellular analytic techniques. iPSC disease models have been widely applied to study monogenic disorders that are caused by a single gene mutation [ 130 ] and sporadic complex disorders involving multiple or unknown genes [ 131 ]. The use of iPSC-based models for the latter disease type is more problematic with respect to monogenic diseases, since the phenotype is often the result of multiple small-effect genetic variants in combination with environmental factors.…”

Section: Ipscsmentioning

confidence: 99%

“…In addition to these issues, compliance with good manufacturing practice is mandatory before the wide-scale transplantation of iPSC-based cell therapy products in humans, e.g., it is imperative to use xeno-free components for all procedures starting from reprogramming through to differentiation, extended to patient delivery, particularly in cases where transplanted cells are incorporated in an extracellular support matrix. However, despite these challenges, the use of iPSC-derived cells in regenerative medicine is continuously progressing, and many different iPSC-derived cells have been used in clinical trials to treat different diseases including ophthalmic, neurological, and cardiac disorders [ 131 ].…”

Section: Ipscsmentioning

confidence: 99%

“Betwixt Mine Eye and Heart a League Is Took”: The Progress of Induced Pluripotent Stem-Cell-Based Models of Dystrophin-Associated Cardiomyopathy

Rovina

Castiglioni

Niro

et al. 2020

IJMS

View full text Add to dashboard Cite

The ultimate goal of precision disease modeling is to artificially recreate the disease of affected people in a highly controllable and adaptable external environment. This field has rapidly advanced which is evident from the application of patient-specific pluripotent stem-cell-derived precision therapies in numerous clinical trials aimed at a diverse set of diseases such as macular degeneration, heart disease, spinal cord injury, graft-versus-host disease, and muscular dystrophy. Despite the existence of semi-adequate treatments for tempering skeletal muscle degeneration in dystrophic patients, nonischemic cardiomyopathy remains one of the primary causes of death. Therefore, cardiovascular cells derived from muscular dystrophy patients’ induced pluripotent stem cells are well suited to mimic dystrophin-associated cardiomyopathy and hold great promise for the development of future fully effective therapies. The purpose of this article is to convey the realities of employing precision disease models of dystrophin-associated cardiomyopathy. This is achieved by discussing, as suggested in the title echoing William Shakespeare’s words, the settlements (or “leagues”) made by researchers to manage the constraints (“betwixt mine eye and heart”) distancing them from achieving a perfect precision disease model.

show abstract

Recent advances in the applications of iPSC technology

Cited by 57 publications

References 111 publications

Future Perspectives in Small-Diameter Vascular Graft Engineering

Future Perspectives in Small-Diameter Vascular Graft Engineering

Novel approaches to liver disease diagnosis and modeling

“Betwixt Mine Eye and Heart a League Is Took”: The Progress of Induced Pluripotent Stem-Cell-Based Models of Dystrophin-Associated Cardiomyopathy

Contact Info

Product

Resources

About